Compare iShares MBS ETF (MBB) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs 22nd Century Group Inc — how do they compare? iShares MBS ETF trades at $92.85, while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). Which is the better fit depends on your goals.
| MBB | XXII | |
|---|---|---|
52-Week High | $96.91 | $801.00 |
52-Week Low | $92.72 | $3.72 |
Market Cap | — | $1.52M |
Sector | — | Technology |
Enterprise Value | — | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB trades at $93.255 with a modest 0.36% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock has demonstrated consistent dividend payments with recent payouts of $0.34 per share. Institutional interest appears positive with Focus Financial Network increasing its stake by 13.8% during the latest reporting period.
The outlook remains cautious given the bearish technical signals, though steady dividend payments provide income stability. Key risks include market volatility and interest rate sensitivity. Investment opportunity lies in the consistent dividend yield and institutional accumulation, but requires monitoring of technical resistance levels around $93.
XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.
The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
